---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-057828"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2026-05-15T20:29:39+00:00"
generated_at: "2026-05-15T20:34:43.159288+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Emmaus Q1 revenue down 18% to $2.0M; net loss widens to $3.3M

## Summary
- Net revenues $2.0M vs $2.4M YoY; U.S. sales fell 33% on generic L-Glutamine competition.
- Net loss of $3.3M ($0.05 EPS) vs $2.3M ($0.04 EPS) YoY, driven by higher other expense.
- Loss from operations improved 16% to $0.8M from $1.0M, reflecting cost-cutting measures.
- MENA segment sales surged 446%, partially offsetting U.S. decline.
- Cash and equivalents $1.1M at March 31, 2026, down from $2.1M at December 31, 2025.

## SEC filing metadata
- accession: 0001213900-26-057828
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2026-05-15T20:29:39+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390026057828/0001213900-26-057828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390026057828/ea0290896-8k_emmauslife.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-057828
- JSON: https://secwatch.observer/filing/0001213900-26-057828.json
- Plain text: https://secwatch.observer/filing/0001213900-26-057828.txt

## Key facts
- Earnings Releases
  Emmaus Life Sciences, Inc. reported three months ended March 31, 2026 results: revenue $2.0 million, net income $3.3 million, EPS $0.05 basic net loss per share.
  - Period: three months ended March 31, 2026
  - Revenue: $2.0 million
  - Net income: $3.3 million
  - EPS: $0.05 basic net loss per share
  - Result: reported results
  source text: Net revenues for the three months ended March 31, 2026 were $2.0 million, compared to $2.4 million in the same period in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390026057828/0001213900-26-057828-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.